Continuous oral contraception: changing times

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 22, Issue 2, 2008, Pages 355-374

  Sulak, Patricia J ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

endometriosis; extended regimen; headache; hormone free interval; menstrual symptoms; oral contraceptive

Indexed keywords

DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS NORGESTREL; GESTAGEN; ORAL CONTRACEPTIVE AGENT; PLACEBO;

ABDOMINAL CRAMP; ACNE; AMENORRHEA; BLOATING; BREAKTHROUGH BLEEDING; BREAST TENDERNESS; CLINICAL TRIAL; COST CONTROL; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSMENORRHEA; ENDOMETRIOSIS; HEADACHE; HEALTH CARE COST; HORMONAL CONTRACEPTION; HUMAN; HYPERTENSION; LIBIDO DISORDER; LOW DRUG DOSE; MENORRHAGIA; MENSTRUAL MIGRAINE; MENSTRUATION DISORDER; MENTAL INSTABILITY; MONOTHERAPY; MOOD DISORDER; MYCOSIS; NAUSEA; ORAL CONTRACEPTION; OVARY CYST; OVARY FOLLICLE DEVELOPMENT; OVULATION; OVULATION INHIBITION; PATIENT COMPLIANCE; PATIENT SATISFACTION; PELVIS PAIN SYNDROME; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SPOTTING; SWELLING; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; UTERUS BLEEDING; VOMITING; WEIGHT GAIN; WITHDRAWAL BLEEDING;

CHEMISTRY, PHARMACEUTICAL; CONTRACEPTION; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, HORMONAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MENSTRUATION; MENSTRUATION DISTURBANCES; OVARY; PITUITARY GLAND; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 39749156448     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpobgyn.2007.08.004     Document Type: Review

References (69)

1. Grimes D.A., Godwin A.J., Rubun A., et al. Ovulation and follicular development associated with three low-dose oral contraceptives: a randomized controlled trial. Obstet Gynecol 83 (1994) 29-34
2. Van der Spuy Z.M., Sohnius U., Pienaar C.A., et al. Gonadotropin and estradiol secretion during the week of placebo therapy in oral contraceptive pill users. Contraception 42 (1990) 597-609
3. Van Heusden A.M., and Fauser B.C. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives. Contraception 59 (1999) 237-243
4. Van Heusden A.M., and Fauser B.C. Residual ovarian activity during oral steroid contraception. Hum Reprod Update 8 (2002) 345-358
5. Van Heusden A.M., Coelingh Bennink H.J., and Fauser B.C. FSH and ovarian response: spontaneous recovery of pituitary-ovarian activity during the pill-free period vs. exogenous recombinant FSH during high-dose combined oral contraceptives. Clin Endocrinol 56 (2002) 509-517
6. Schlaff W.D., Lynch A.M., Hughes H.D., et al. Manipulation of the pill-free interval in oral contraceptive pill users: the effect on follicular suppression. Am J Obstet Gynecol 190 (2004) 943-951
7. Pierson R., Archer D., Moreau M., et al. Ortho EVRA™ vs oral contraceptives: follicular development and ovulation in normal cycles and after intentional dosing error. Fertil Steril 80 (2003) 34-42
8. Baerwald A.R., Olatunbosun O.A., and Peirson R.A. Effects of oral contraceptives administered at defined stages of ovarian follicular development. Fertil Steril 86 (2006) 27-35
9. Baerwald A.R., Olatunbosun O.A., and Peirson R.A. Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use. Contraception 70 (2004) 371-377
10. Willis S., Kuehl T.J., Spiekerman A.M., et al. Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception 74 (2006) 100-103
11. Sullivan H., Furniss H., Spona J., et al. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 μg) and ethinyl estradiol (15 μg) on ovarian activity. Fertil Steril 72 (1999) 115-120
12. Fitzgerald C., Feichtinger W., Spona J., et al. A comparison of the effects of two monophasic low dose oral contraceptives on the inhibition of ovulation. Adv Contracept 10 (1994) 5-18
13. Spona J., Elstein M., Feichtinger W., et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 54 (1996) 71-77
14. Holt V.L., Cushing-Haugen K.L., and Daling J.R. Oral contraceptives, tubal sterilization, and functional ovarian cyst risk. Obstet Gynecol 102 (2003) 252-258
15. Oinonen K.A., and Mazmanian D. To what extent do oral contraceptives influence mood and affect. J Affect Disord 70 (2002) 229-240
16. Food and Drug Administration. Guidance for Industry. Combined Oral Contraceptive Labeling for Healthcare Providers and Patients (2000), U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. http://www.fda.gov/cder/guidance/2448dft.pdf [Last accessed 16.06.07]
17. Sulak P.J., Scow R.D., Preece C., et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 95 (2000) 261-266
18. Bäckström T., Hansson-Malmström Y., Lindhe B., et al. Oral contraceptives in premenstrual syndrome: a randomized comparison of triphasic and monophasic preparations. Contraception 46 (1992) 253-268
19. Huber L.R., Hogue C.J., Stein A.D., et al. Contraceptive use and discontinuation: findings from the contraceptive history, initiation, and choice study. Am J Obstet Gynecol 194 (2006) 1290-1295
20. Rosenberg M.J., Waugh M.S., and Meehan T.E. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 51 (1995) 283-288
21. Rosenberg M.J., and Waugh M.S. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 179 (1998) 577-582
22. Loudon N.B., Foxwell M., Potts D.M., et al. Acceptability of an oral contraceptive that reduces the frequency of menstruation: the tri-cycle pill regimen. BMJ 2 (1977) 187-190
23. Cachrimanidou A.C., Hellberg D., Nilsson S., et al. Long interval treatment regimen with a desogestrel-containing oral contraceptive. Contraception 48 (1993) 205-216
24. Kovacs G.T., Rusden J., and Evans A. A trimonthly regimen for oral contraceptives. Br J Fam Plan 19 (1994) 274-275
25. Bachman G., Sulak P.J., Sampson-Landers C., et al. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception 70 (2004) 191-198
26. ®24 Fe). Contraception 75 (2007) 16-22
27. Anderson F.D., and Hait H. the Seasonale-301 Study Group. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 68 (2003) 89-96
28. Anderson F.D., Gibbons W., and Portman D. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception 73 (2006) 229-234
29. Archer D.F., Jensen J.T., Johnson J.V., et al. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 results. Contraception 74 (2006) 439-445
30. Miller L., and Notter K.M. Menstrual reduction with extended use of combination oral contraceptive controlled trial. Obstet Gynecol 98 (2001) 771-778
31. Kweicien M., Edelman A., Nichols M.D., et al. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception 67 (2003) 9-13
32. Miller L., and Verhoeven C.H.J. Results of a randomized multicenter trial comparing extended contraceptive ring regimens. Obstet Gynecol 105 Suppl (2005) 16S (abstract)
33. Stewart F.H., Kaunitz A.M., La Guardia K.D., et al. Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial. Obstet Gynecol 105 (2005) 1389-1396
34. Anderson F.D., Gibbons W., and Portman D. Long-term safety of an extended-cycle oral contraceptive (Seasonale): a 2-year multicenter open-label extension trial. Am J Obstet Gynecol 195 (2006) 92-96
35. Mishell D.R., Guillebaud J., Westhoff C., et al. Combined hormonal contraceptive trials: variable data collection and bleeding assessment methodologies influence study outcomes and physician perception. Contraception 75 (2007) 4-10
36. Sulak P.J., Kuehl T.J., Coffee A., et al. Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen. Am J Obstet Gynecol 195 (2006) 935-941
37. Silberstein S.D., and Merrian G.R. Physiology of the menstrual cycle. Cephalgia 20 (2000) 148-154
38. Mattsson P. Hormonal factors in migraine: a population-based study of women aged 40-74 years. Headache 43 (2003) 27-35
39. MacGregor E.A. Oestrogen and attacks of migraine with and without aura. Lancet Neurol 3 (2004) 354-361
40. Loder E. Menstrual migraine. Curr Treat Options Neurol 3 (2001) 189-200
41. Allais G., and Benedetto C. Update on menstrual migraine: from clinical aspects to therapeutic struggle. Neurol Sci 25 Suppl. 3 (2004) S229-S231
42. Sulak P.J., Kuehl T.J., Ortiz M., et al. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 186 (2002) 1142-1149
43. Kelman L. Women's issues of migraine in tertiary care. Headache 44 (2004) 2-7
44. Sulak P.J., Cressman B.E., Waldrop E., et al. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol 89 (1997) 179-183
45. Sulak P.J., Carl J., Gopalakrishan I., et al. Outcomes of extended oral contraceptive regimens with a shortened hormone-free interval to manage breakthrough bleeding. Contraception 70 (2004) 281-287
46. Sillem M., Schneidereit R., Heithecker R., et al. Use of an oral contraceptive containing drospirenone in an extended regimen. Eur J Contracept Reprod Health Care 8 (2003) 162-169
47. Miller L., and Hughes J.P. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol 101 (2003) 653-661
48. Sulak P., Willis S., Kuehl T., et al. Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. Headache 47 (2007) 27-37
49. Coffee A.L., Kuehl T.J., Willis S., et al. Oral contraceptive and premenstrual symptoms: comparison of a 21/7 and an extended regimen. Am J Obstet Gynecol 195 (2006) 1311-1319
50. Yonkers K.A., Brown C., Pearlstein T.B., et al. Efficacy of a new low-dose oral contraceptive with drosperinone in premenstrual dysphoric disorder. Obstet Gynecol 106 (2005) 492-501
51. Vercellini P., Frontino G., DeGiorgi O., et al. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril 80 (2003) 560-563
52. Kjerluff K.H., Erickson B.A., and Langenberg P.W. Chronic gynecological conditions reported by US women: findings from the National Health Survey, 1984 to 1992. Am J Public Health 86 (1996) 195-199
53. Braunstein J.B., Hausfeld J., Hausfeld J., et al. Economics of reducing menstruation with trimonthly-cycle oral contraceptive therapy: comparison with standard-cycle regimens. Obstet Gynecol 102 (2003) 699-708
54. Eaton S.B., Pike M.C., Short R.V., et al. Women's reproductive cancers in evolutionary context. Q Rev Biol 69 (1994) 353-367
55. Davis A., and Westhoff C.L. Primary dysmenorrhea in adolescent girls and treatment with oral contraceptives. J PediatrAdoles Gyn 14 (2001) 3-8
56. Coté I., Jacobs P., and Cumming D. Work loss associated with increased menstrual loss in the United States. Obstet Gynecol 100 (2002) 683-687
57. Miller W.B., and Smith P.J. Elimination of the menses: psychosocial aspects. J Psychiatr Res 12 (1975) 153-166
58. Rutter W., Knight C., Vizzard J., et al. Women's attitudes to withdrawal bleeding and their knowledge and beliefs about the oral contraceptive pill. Med J Aust 149 (1988) 417-419
59. den Tonkelaar I., and Oddens B. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, hormone replacement therapy. Contraception 59 (1999) 357-362
60. Andrist L.C., Hoyt J., Weinstein D., et al. The need to bleed: women's attitudes and beliefs about menstrual suppression. J Am Acad Nurse Pract 16 (2004) 31-37
61. Andrist L.C., Arias R.D., Nucatola D., et al. Women's and providers' attitudes toward menstrual suppression with extended use of oral contraceptives. Contraception 70 (2004) 359-363
62. Association of Reproductive Health Professionals. Choosing When to Menstruate: the Role of Extended Contraception (2003), Association of Reproductive Health Professionals. http://www.arhp.org/healthcareproviders/cme/onlinecme/extendedregimencp/ index.cfm?ID=328 [Last accessed 30. 05. 06]
63. Ferrero S., Abbamonte L.H., Giordano M., et al. What is the desired menstrual frequency of women without menstruation-related symptoms?. Contraception 73 (2006) 537-541
64. Weigratz I., Hommel H.H., Zimmermann T., et al. Attitude of German women and gynecologists towards long-cycle treatment with oral contraceptives. Contraception 69 (2004) 37-42
65. Glasier A.F., Smith K.B., van der Spuy Z.M., et al. Amenorrhea associated with contraception - an international study on acceptability. Contraception 67 (2003) 1-8
66. Machado R.B., Fabrini P., Cruz A.M., et al. Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 μg) and gestodene (75 μg). Contraception 70 (2004) 365-370
67. van den Heuvel M.W., van Bragt A.J.M., Alnabawy A.K.M., et al. Comparison of ethinylestradiol pharmacokinetics in three hormone contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 72 (2005) 168-174
68. ESHRE Capri Workshop Group. Ovarian and endometrial function during hormonal contraception. Hum Reprod 16 (2001) 1527-1535
69. Anderson F.D., Hait H., Hsiu J., et al. Endometrial microstructure following long-term use of a 91-day extended cycle oral contraceptive regimen. Contraception 71 (2005) 55-59